Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
64
Language
English
Published on
31/01/25
You may also be interested by these reports :
12/11/26
Sonova’s H1 results exceeded expectations. The Hearing Instruments segment drove sales growth, partly offset by weakness in Cochlear Implants. ...
12/11/26
Ottobock delivered a solid 3Q26, in line on sales and slightly ahead on profitability. Core revenues grew by +9.0% to €433.4m (organic +6.4%). B2B ...
11/11/26
The Q3 sales and profitability met expectations; however, a slight guidance downgrade disappointed investors. Healthy growth in all sub-segments was ...
09/11/26
Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US ...